More on Rifampin Prophylaxis againstHaemophilus influenzaeb in Day-Care Facilities

Abstract

To the Editor: A Special Report in the May 7 issue¹ by some of the members of the Immunization Practices Advisory Committee (ACIP) and staff members of the Centers for Disease Control, was not a formal statement by the ACIP. Rather, it was a discussion of the rationale for the ACIP's recommendations on the use of rifampin chemoprophylaxis for the prevention of secondary cases of Haemophilus influenzae b disease.¹ In that article we raised issues pertaining to the Minnesota and Texas studies^{2 , 3} in an attempt to explain differences in the occurrence of secondary H. influenzae b disease in day-care facilities. . . .